207 related articles for article (PubMed ID: 27896933)
1. Feasibility and clinical integration of molecular profiling for target identification in pediatric solid tumors.
Pincez T; Clément N; Lapouble E; Pierron G; Kamal M; Bieche I; Bernard V; Fréneaux P; Michon J; Orbach D; Aerts I; Pacquement H; Bourdeaut F; Jiménez I; Thébaud E; Oudot C; Vérité C; Taque S; Owens C; Doz F; Le Tourneau C; Delattre O; Schleiermacher G
Pediatr Blood Cancer; 2017 Jun; 64(6):. PubMed ID: 27896933
[TBL] [Abstract][Full Text] [Related]
2. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
[TBL] [Abstract][Full Text] [Related]
3. Molecular Screening for Cancer Treatment Optimization (MOSCATO-01) in Pediatric Patients: A Single-Institutional Prospective Molecular Stratification Trial.
Harttrampf AC; Lacroix L; Deloger M; Deschamps F; Puget S; Auger N; Vielh P; Varlet P; Balogh Z; Abbou S; Allorant A; Valteau-Couanet D; Sarnacki S; Gamiche-Rolland L; Meurice G; Minard-Colin V; Grill J; Brugieres L; Dufour C; Gaspar N; Michiels S; Vassal G; Soria JC; Geoerger B
Clin Cancer Res; 2017 Oct; 23(20):6101-6112. PubMed ID: 28733441
[No Abstract] [Full Text] [Related]
4. Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy.
Kline CN; Joseph NM; Grenert JP; van Ziffle J; Talevich E; Onodera C; Aboian M; Cha S; Raleigh DR; Braunstein S; Torkildson J; Samuel D; Bloomer M; Campomanes AGA; Banerjee A; Butowski N; Raffel C; Tihan T; Bollen AW; Phillips JJ; Korn WM; Yeh I; Bastian BC; Gupta N; Mueller S; Perry A; Nicolaides T; Solomon DA
Neuro Oncol; 2017 May; 19(5):699-709. PubMed ID: 28453743
[TBL] [Abstract][Full Text] [Related]
5. Discovery of actionable genetic alterations with targeted panel sequencing in children with relapsed or refractory solid tumors.
Lee JW; Kim NKD; Lee SH; Cho HW; Ma Y; Ju HY; Yoo KH; Sung KW; Koo HH; Park WY
PLoS One; 2019; 14(11):e0224227. PubMed ID: 31747416
[TBL] [Abstract][Full Text] [Related]
6. Molecular-guided therapy for the treatment of patients with relapsed and refractory childhood cancers: a Beat Childhood Cancer Research Consortium trial.
Sholler GLS; Bergendahl G; Lewis EC; Kraveka J; Ferguson W; Nagulapally AB; Dykema K; Brown VI; Isakoff MS; Junewick J; Mitchell D; Rawwas J; Roberts W; Eslin D; Oesterheld J; Wada RK; Pastakia D; Harrod V; Ginn K; Saab R; Bielamowicz K; Glover J; Chang E; Hanna GK; Enriquez D; Izatt T; Halperin RF; Moore A; Byron SA; Hendricks WPD; Trent JM
Genome Med; 2024 Feb; 16(1):28. PubMed ID: 38347552
[TBL] [Abstract][Full Text] [Related]
7. Implementation of next generation sequencing into pediatric hematology-oncology practice: moving beyond actionable alterations.
Oberg JA; Glade Bender JL; Sulis ML; Pendrick D; Sireci AN; Hsiao SJ; Turk AT; Dela Cruz FS; Hibshoosh H; Remotti H; Zylber RJ; Pang J; Diolaiti D; Koval C; Andrews SJ; Garvin JH; Yamashiro DJ; Chung WK; Emerson SG; Nagy PL; Mansukhani MM; Kung AL
Genome Med; 2016 Dec; 8(1):133. PubMed ID: 28007021
[TBL] [Abstract][Full Text] [Related]
8. Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors.
Nikiforova MN; Wald AI; Melan MA; Roy S; Zhong S; Hamilton RL; Lieberman FS; Drappatz J; Amankulor NM; Pollack IF; Nikiforov YE; Horbinski C
Neuro Oncol; 2016 Mar; 18(3):379-87. PubMed ID: 26681766
[TBL] [Abstract][Full Text] [Related]
9. Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study.
Harris MH; DuBois SG; Glade Bender JL; Kim A; Crompton BD; Parker E; Dumont IP; Hong AL; Guo D; Church A; Stegmaier K; Roberts CWM; Shusterman S; London WB; MacConaill LE; Lindeman NI; Diller L; Rodriguez-Galindo C; Janeway KA
JAMA Oncol; 2016 May; 2(5):608-615. PubMed ID: 26822149
[TBL] [Abstract][Full Text] [Related]
10. Pediatric Sarcomas Are Targetable by MR-Guided High Intensity Focused Ultrasound (MR-HIFU): Anatomical Distribution and Radiological Characteristics.
Shim J; Staruch RM; Koral K; Xie XJ; Chopra R; Laetsch TW
Pediatr Blood Cancer; 2016 Oct; 63(10):1753-60. PubMed ID: 27199087
[TBL] [Abstract][Full Text] [Related]
11. Profiling of potential driver mutations in sarcomas by targeted next generation sequencing.
Andersson C; Fagman H; Hansson M; Enlund F
Cancer Genet; 2016 Apr; 209(4):154-60. PubMed ID: 26987750
[TBL] [Abstract][Full Text] [Related]
12. Molecular Profiling of Hard-to-Treat Childhood and Adolescent Cancers.
Khater F; Vairy S; Langlois S; Dumoucel S; Sontag T; St-Onge P; Bittencourt H; Dal Soglio D; Champagne J; Duval M; Leclerc JM; Laverdiere C; Tran TH; Patey N; Ellezam B; Perreault S; Piché N; Samson Y; Teira P; Jabado N; Michon B; Brossard J; Marzouki M; Cellot S; Sinnett D
JAMA Netw Open; 2019 Apr; 2(4):e192906. PubMed ID: 31026031
[TBL] [Abstract][Full Text] [Related]
13. Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome.
Padovan-Merhar OM; Raman P; Ostrovnaya I; Kalletla K; Rubnitz KR; Sanford EM; Ali SM; Miller VA; Mossé YP; Granger MP; Weiss B; Maris JM; Modak S
PLoS Genet; 2016 Dec; 12(12):e1006501. PubMed ID: 27997549
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of implementing molecular-guided therapy for the treatment of patients with relapsed or refractory neuroblastoma.
Saulnier Sholler GL; Bond JP; Bergendahl G; Dutta A; Dragon J; Neville K; Ferguson W; Roberts W; Eslin D; Kraveka J; Kaplan J; Mitchell D; Parikh N; Merchant M; Ashikaga T; Hanna G; Lescault PJ; Siniard A; Corneveaux J; Huentelman M; Trent J
Cancer Med; 2015 Jun; 4(6):871-86. PubMed ID: 25720842
[TBL] [Abstract][Full Text] [Related]
15. Molecular Biology in Pediatric High-Grade Glioma: Impact on Prognosis and Treatment.
Rizzo D; Ruggiero A; Martini M; Rizzo V; Maurizi P; Riccardi R
Biomed Res Int; 2015; 2015():215135. PubMed ID: 26448930
[TBL] [Abstract][Full Text] [Related]
16. Neuron navigator 3 alterations in nervous system tumors associate with tumor malignancy grade and prognosis.
Carlsson E; Krohn K; Ovaska K; Lindberg P; Häyry V; Maliniemi P; Lintulahti A; Korja M; Kivisaari R; Hussein S; Sarna S; Niiranen K; Hautaniemi S; Haapasalo H; Ranki A
Genes Chromosomes Cancer; 2013 Feb; 52(2):191-201. PubMed ID: 23097141
[TBL] [Abstract][Full Text] [Related]
17. Next-generation personalised medicine for high-risk paediatric cancer patients - The INFORM pilot study.
Worst BC; van Tilburg CM; Balasubramanian GP; Fiesel P; Witt R; Freitag A; Boudalil M; Previti C; Wolf S; Schmidt S; Chotewutmontri S; Bewerunge-Hudler M; Schick M; Schlesner M; Hutter B; Taylor L; Borst T; Sutter C; Bartram CR; Milde T; Pfaff E; Kulozik AE; von Stackelberg A; Meisel R; Borkhardt A; Reinhardt D; Klusmann JH; Fleischhack G; Tippelt S; Dirksen U; Jürgens H; Kramm CM; von Bueren AO; Westermann F; Fischer M; Burkhardt B; Wößmann W; Nathrath M; Bielack SS; Frühwald MC; Fulda S; Klingebiel T; Koscielniak E; Schwab M; Tremmel R; Driever PH; Schulte JH; Brors B; von Deimling A; Lichter P; Eggert A; Capper D; Pfister SM; Jones DT; Witt O
Eur J Cancer; 2016 Sep; 65():91-101. PubMed ID: 27479119
[TBL] [Abstract][Full Text] [Related]
18. Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.
Stockley TL; Oza AM; Berman HK; Leighl NB; Knox JJ; Shepherd FA; Chen EX; Krzyzanowska MK; Dhani N; Joshua AM; Tsao MS; Serra S; Clarke B; Roehrl MH; Zhang T; Sukhai MA; Califaretti N; Trinkaus M; Shaw P; van der Kwast T; Wang L; Virtanen C; Kim RH; Razak AR; Hansen AR; Yu C; Pugh TJ; Kamel-Reid S; Siu LL; Bedard PL
Genome Med; 2016 Oct; 8(1):109. PubMed ID: 27782854
[TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of integrated panel testing by next-generation sequencing for somatic mutations in neuroblastomas with MYCN unamplification.
Cao Y; Jin Y; Yu J; Wang J; Qiu Y; Duan X; Ye Y; Cheng Y; Dong L; Feng X; Wang D; Li Z; Tian X; Wang H; Yan J; Zhao Q
Oncotarget; 2017 Jul; 8(30):49689-49701. PubMed ID: 28591696
[TBL] [Abstract][Full Text] [Related]
20. Next-Generation Sequencing for Patients with Sarcoma: A Single Center Experience.
Cote GM; He J; Choy E
Oncologist; 2018 Feb; 23(2):234-242. PubMed ID: 28860410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
